Aduro Biotech

ADRO

7.55

+0.25

+3.4%

Please Login or Register

Login|Register FREE

Stock Price
Open: 7.25
Prev. Close: 7.30
Low/Hi: 7.25 - 7.65
52-Week: 6.01 - 14.05
Volumes
Equity: 229,454
90-Day Avg: 515,123
Option: 62
90-Day Avg: 71
Volatility
Todays Stock Vol: 59.9
20-Day (HV): 55.6
52-Week (HV): 54.6
30-Day IV: 66.3 -1.0
IV Pct Rank: 2% Subdued
Fundamental
Div. Yield:
Earnings: 1-Mar (Est.)
P/E Ratio:
Market Cap: 564.3 M
Short Int Pct: 0.0%
Pct Held By Inst.: 66.1%
Stock Info
Type: Common
Sector: Healthcare
Industry: Biotechnology

ADRO Company Events

Upcoming Events
Event Event Date Location Info
No Upcoming Events
Past Events
Event Event Date Location Info
36th Annual J.P. Morgan Healthcare Conference Jan 11, 12:00 PM
59th American Society of Hematology (ASH) Annual Meeting Dec 10, 2017
Society for Immunotherapy of Cancers 32nd Annual Meeting Nov 10, 2017
Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology Sep 28, 1:00 PM
Cantor Fitzgerald Global Healthcare Conference Sep 27, 8:35 AM
Ladenburg Thalmann 2017 Healthcare Conference Sep 26, 8:30 AM
18th Annual Rodman & Renshaw Global Investment Conference Sep 11, 11:15 AM
24th Annual BioCentury NewsMakers Conference Sep 8, 8:30 AM
2017 Baird Global Healthcare Conference Sep 7, 7:55 AM
37th Annual Canaccord Genuity Growth Conference Aug 10, 12:00 PM
2017 American Society of Clinical Oncology (ASCO) Annual Meeting Jun 3, 7:00 AM
Bank of America Merrill Lynch 2017 Heath Care Conference May 18, 1:00 PM
42nd Annual Deutsche Bank Health Care Conference May 3, 8:00 AM
2017 American Association for Cancer Research Annual Meeting Apr 1, 2017 - Apr 5, 2017
Research and Development Day Mar 27, 8:30 AM
Keystone Symposia on Cancer Immunology and Immunotherapy Conference Mar 19, 2017 - Mar 23, 2017
29th Annual ROTH Conference Mar 13, 2017
37th Cowen and Company Annual Healthcare Conference Mar 6, 2017
Leerink Partners 6th Annual Global Healthcare Conference Feb 16, 9:00 AM
35th Annual J.P. Morgan Healthcare Conference Jan 9, 1:00 PM
LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology Sep 29, 2016 New York, NY
Leerink Partners Rare Disease & IO Roundtable Series Sep 29, 8:00 AM
36th Annual Canaccord Genuity Growth Conference Aug 11, 2016 Boston, MA
ROTH Healthcare Day Jun 22, 2016
NASDAQ Investor Conference Jun 16, 10:15 AM
i

Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, will present

2016 Bank of America Health Care Conference May 10, 2:20 PM Las Vegas, NV
41st Annual Deutsche Bank Health Care Conference May 4, 10:00 AM Boston, MA
STING Activation in Cancer Immunotherapy in a Major Symposium Apr 16, 2016 - Apr 20, 2016 New Orleans, Louisiana
i

presentation will focus on ADU-S100, a novel synthetic cyclic dinucleotide (CDN) that is one of a family of proprietary small molecules being developed by Aduro that broadly activates the human STING receptor. STING is expressed in immune cells that are present in the tumor microenvironment (TME) and is a central and potent mediator of the innate immune response, a necessary step in the development of effective tumor-specific immunity. Activation of the STING pathway has been shown to correlate with infiltration of lymphocytes and a T-cell inflamed TME in patients with melanoma. Stimulation of STING induces signaling through several innate immune response pathways, resulting in the expression of various interferons, cytokines and T cell recruitment factors that amplify and strengthen immune activity. Dr. Dubensky will discuss preclinical data demonstrating that the direct engagement of STING through the intratumoral injection of ADU-S100 resulted in effective, durable and systemic anti-tumor activity. The data suggest that the resulting tumor regression is due to an acute pro-inflammatory cytokine response and induction of tumor-specific CD8+ T cell immunity. Preclinical data will be presented which also demonstrate the potential synergistic effects of combining ADU-S100 and immune checkpoint inhibitors, including anti-PD1. In addition, Dr. Dubensky will present an overview of the Phase 1 clinical trial to evaluate the safety, tolerability and possible anti-tumor activity of ADU-S100 given by intratumoral injection to patients with advanced cutaneously accessible solid tumors or lymphomas.

ROTH Conference Mar 14, 2016 Laguna Niguel, CA
i

Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, will present

Leerink Partners Global Healthcare Conference Feb 10, 8:25 AM New York, NY
i

Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, was invited to present

JP Morgan Healthcare Conference Jan 14, 2016 San Francisco, CA
i

Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, was invited to present

Oppenheimer Healthcare Conference Dec 9, 9:45 AM
i

Gregory W. Schafer, chief operating officer of Aduro, will present

33rd NASDAQ Investor Conference Dec 1, 8:00 AM in London, UK
i

Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, will present

conference cal Nov 25, 2015
European Society for Medical Oncology (ESMO) Symposium on Immuno-Oncology 2015, Nov 20, 2015 - Nov 21, 2015 Lausanne, Switzerland
i

presentation of an overview of novel antibody and combination strategies designed to stimulate durable anti-tumor response

Credit Suisse Healthcare Conference Nov 11, 1:00 PM
i

Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, will present

Leerink Partners Immuno-Oncology Roundtable Oct 1, 2015
i

Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, will participate in an analyst led fireside chat at the Leerink Partners Immuno-Oncology Roundtable

BioCentury's NewsMakers in the Biotech Industry Conference Sep 10, 2015
i

Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, will present

35th Annual Canaccord Genuity Growth Conference Aug 12, 2015
i

Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, will present

Bank of America Merrill Lynch 2015 Health Care Conference May 14, 12:20 PM

Wait, Before You Leave...

Want to Know More About ADRO Earnings?

Receive your FREE email to get Wall Street expected earnings moves and daily upcoming earnings alerts!
Market Chameleon